We're here to help during Covid-19. Find out more here.
This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of GDC-9545 in participants with Stage I-III operable ER+, HER2- untreated breast cancer.
Who is it for?
You may be eligible for this study if you meet the below criteria:
Participants will receive varying dosages of GDC-9545 once daily, starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Subscribe for updates & stay in the loop with new studies.